National and Kapodistrian University of Athens
Ο ρόλος των αρχέγονων ενδοθηλιακών κυττάρων στην καρδιακή ανεπάρκεια: η επίδραση της ροσουβαστατίνης και της αλλοπουρινόλης
Abstract
dc:descriptionPurpose: Evidence suggests that endothelial progenitor cells (EPCs) play a significant role in the reendothelialisation and vascular repair while reduced number of EPCs identifies patients at increased risk tor major adverse cardiac events. We investigated the effect of rosuvastatin and allopurinol on the number of EPCs in patients with heart failure and the relations of pro inflammatory cytokines and oxidative stress to the levels of these cells. Methods: Sixty clinically stable patients with systolic heart failure were randomized double blind to receive rosuvastatin 10 mg/d allopurinol 300 mg/d or placebo and followed up for 1 month. The number of EPCs (CD34⁺/KDR⁺ and CD34⁺/AC133⁺/KDR⁺) in blood was evaluated by flow cytometry. Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD). Levels of myeloperoxidase (MPO) and total lipid peroxides in plasma as well as vascular endothelial growth factor soluble CD40 ligand (sCD40L) matrix metalloproteinase-9 interleukin-6 (IL-6) IL-Iβ and oxidized LDL in serum were determined by ELISA. Results: CD34⁺/KDR⁺ and CD34⁺/AC133⁺/KDR⁺ cells were significantly increased in rosuvastatin treated group (from 0.023 (0.017-0.038) and 0.001 (0.0008-0.0024) to 0.039 (0.023-0.052) cells/100 mononuclear cells (MNCs) and 0.0019 (0.0008-0.0033) cells/100 MNCs respectively p=0 004 and p=0 008) whereas they remained unchanged in the other groups. The increase in levels of CD34⁺/KDR⁺ EPCs induced by rosuvastatin was significantly greater compared with that induced by allopurinol and placebo (difference between groups p<0.05). A significant improvement in FMD was seen after both rosuvastatin (p=0.02) and allopurinol (p=0.004) treatment. There was no significant correlation between baseline EPC number and FMD. In the entire study group a significant correlation was observed between the baseline levels of CD34⁺/KDR⁺ cells and MPO (r=0.351 p=0.005) and sCD40L (r=0.313 p=0.013). After controlling for potential confounders only body mass index (β=-0.39 p=0.049) and MPO levels (β=0.49 p=0.047) were significant predictors of EPC numbers. Conclusions: Short term treatment with rosuvastatin but not allopurinol significantly increases the number of circulating EPCs in patients with heart failure providing further insights into its role in such patients. Furthermore, EPC levels are significantly associated with plasma levels of MPO suggesting a possible role of MPO in the mobilisation of EPCs in such individuals.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ανδρέου, Ιωάννης
- Andreou, Ioannis
Subjects
dc:subject × 20- Καρδιακή ανεπάρκεια
- Προγονικά ενδοθηλιακά κύτταρα
- Στατίνες
- Ροσουβαστατίνη
- Αλλοπουρινόλη
- Φλεγμονές
- Οξειδωτικό φορτίο
- Αναστολείς ξανθινοξειδάσης
- Heart failure
- Endothelial progenitor cells
- Statins
- Rosuvastatin
- Allopurinol
- Inflammation
- Oxidative stress
- Xanthineoxidase inhibitors
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27905